KENALOG-10 (triamcinolone acetonide)
KENALOG-10 is indicated for the treatment of Gouty Arthritis; Bursitis; Tenosynovitis; Epicondylitis; Rheumatoid Arthritis; Synovitis of Osteoarthritis; Alopecia Areata; Discoid Lupus Erythematosus; Keloids; Granuloma Annulare; Lichen Planus; Lichen Simplex Chronicus; Psoriatic Plaques; Necrobiosis Lipoidica Diabeticorum.
Details
- Status
- Prescription
- First Approved
- 1960-01-04
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
KENALOG-10 Approval History
What KENALOG-10 Treats
14 indicationsKENALOG-10 is approved for 14 conditions since its original approval in 1960. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Gouty Arthritis
- Bursitis
- Tenosynovitis
- Epicondylitis
- Rheumatoid Arthritis
- Synovitis of Osteoarthritis
- Alopecia Areata
- Discoid Lupus Erythematosus
KENALOG-10 Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in KENALOG-10's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications KENALOG-10 treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to KENALOG-10
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
58 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04207931 CCCA | IRB00043796 | Ph 4 | recruiting | Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study |
| NCT07453238 CALISTA-AA | AA-RCT-2026-01 | Ph 4 | not yet recruiting | Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata |
| NCT05436535 LEADS | DAIT ADRN-12 | Ph 4 | completed | Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis |
| NCT04002362 results posted | IRB00111087 R01NR018666 | Ph 2 | completed | Symptom Clusters in Children With Exacerbation-prone Asthma |
| NCT06401317 CASITOA | CASITOA | Ph 2 | recruiting | Corticosteroid Against Saline Injections for Thumb Osteoarthritis (CASITOA) |
| NCT06977568 | 006-C-202 | Ph 2 | terminated | A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip |
| NCT05190770 results posted | 21-091 | Ph 2 | completed | A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer |
| NCT05535738 | STUDY00000321 | Ph 2, Ph 3 | active not recruiting | Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation |
| NCT07189572 | UHCT250873 | Ph 3 | not yet recruiting | Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma |
| NCT07141446 | GDCH/IEC/I-2024(04) | Ph 1, Ph 2 | completed | Evaluation of Efficacy of Neem (Azadirachta Indica) Versus Triamcinolone Acetonide in the Treatment of Oral Lichen Planus. |
| NCT07114016 | FDASU-REC0787 | Ph 4 | completed | Efficacy of Topical Glucosamine Versus Corticosteroid in Oral Lichen Planus |
| NCT04469075 | 19-342 | Ph 2 | active not recruiting | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields |
| NCT07100145 | FDASU-Rec IM012414 | Ph 4 | not yet recruiting | Efficacy of Coconut Gel Compared to Corticosteroid Gel in the Management of Oral Lichen Planus |
| NCT07014280 | BevaVSsteroid:keloids | Ph 4 | active not recruiting | Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids. |
| NCT04731233 results posted | IRB202000689-A OCR40106 | Ph 4 | terminated | Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis |
| NCT06814288 | DV-202501.01 | Ph 2 | active not recruiting | The Effectiveness of Intralesional Botulinum Toxin A and Triamcinolone Acetonide Injections in Keloid Treatment |
| NCT06810752 | 24-092 | Ph 1, Ph 2 | enrolling by invitation | Thyme Honey for Management of Oral Lichen Planus |
| NCT05806021 | 21.411 | Ph 4 | recruiting | The Efficacy of Intra-articular Triamcinolone Acetonide 5mg vs. 10 mg vs. 40 mg in Patients With Knee Osteoarthritis |
| NCT05512962 CAPE results posted | OXUCT-103 - CAPE 2022-001533-37 | Ph 2 | completed | Oxulumis® Suprachoroidal Microcatherization of Triesence® in Diabetic Macular Edema |
| NCT05158699 EPICAT | NL72427.068.19 2019-004890-21 | Ph 3 | terminated | Effectiveness of Periocular Drug Injection in CATaract Surgery |
| NCT06524323 | 2024-0042 | Ph 3 | not yet recruiting | A Randomized, Double-blinded, Self-controlled Clinical Study of Intralesional Injection of 5-fluorouracil Plus Triamcinolone for the Treatment of Refractory Nodular Prurigo |
| NCT03166761 results posted | SCHNEIBJ03152017153735 | Ph 4 | terminated | Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection |
| NCT04075136 | IRB00058375 | Ph 4 | withdrawn | Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy |
| NCT03636373 results posted | Pro2018000562 | Ph 4 | terminated | Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout |
| NCT05413330 | UDMS-Opthal-01-2022 | Ph 2, Ph 3 | completed | Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes. |
| NCT03293368 | PRP-olp | Ph 2 | completed | Efficacy of Intralesional Injection of Platelet Rich Plasma in the Treatment of Patients With Erosive Oral Lichen Planus |
| NCT03382925 results posted | 106288 | Ph 4 | terminated | Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness? |
| NCT05429450 TOMATO | MD-139-2020 | Ph 2 | completed | Thyroid Associated Orbitopathy Treatment by Methotrexate Against Triamcinolone Periocular Injections |
| NCT03627741 | 17-008766 | Ph 1 | completed | A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors |
| NCT03248856 | 1456/2017 2017-002377-19 | Ph 1 | completed | Triamcinolone Levels in Cochlear Perilymph |
| NCT02873026 ASCOT | CHAD1031 | Ph 3 | completed | Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study |
| NCT04976673 | kb256/2020 | Ph 2 | completed | Comparison of Clinical Efficiency of Photodynamic Therapy and Topical Corticosteroid in Treatment of Oral Lichen Planus |
| NCT01572350 ALBA | ALBA09 | Ph 3 | completed | Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema |
| NCT02877485 results posted | IRB-36535 | Ph 4 | completed | The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation |
| NCT02025023 CTS | STUDY00003748 | Ph 3 | recruiting | Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study |
| NCT02221453 | PersDMEcytokineTA | Ph 2 | completed | Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide |
| NCT02120261 USAMPS results posted | HSC-MS-14-0072 | Ph 4 | terminated | Using Saline for Myofascial Pain Syndromes (USAMPS) |
| NCT03319784 | STUDY00008014 | Ph 4 | withdrawn | Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients |
| NCT02598869 | 00011584 | Ph 4 | withdrawn | Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema |
| NCT02294656 | ML27905 | Ph 1 | completed | Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide |
| NCT03535233 | AA22 | Ph 4 | completed | Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata |
| NCT03120923 | HE551338 | Ph 4 | completed | Combined Corticosteroid With Low Volume Compared to High Volume in Impingement Syndrome |
| NCT01230424 results posted | NIH NIAMS R01-AR057802 Tufts MC IRB Protocol # 9417 | Ph 4 | completed | Effect of Steroid Injections in a Knee With Osteoarthritis |
| NCT01362608 results posted | CACZ885H2358 2010-024172-26 | Ph 3 | terminated | Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective |
| NCT01978301 | 117287 | Ph 1 | terminated | Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars |
| NCT01774474 PREMED | NL42463.068.12 | Ph 3 | completed | PRevention of Macular EDema After Cataract Surgery |
| NCT02828163 | PRP # steroids in pemphigus | Ph 3 | completed | Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris |
| NCT02329600 results posted | polyphenol_TOC_OLP | Ph 3 | completed | Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus |
| NCT02022930 | COR1.1 | Ph 3 | completed | Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis |
| NCT02858297 | FDASU-RECD 1214403 | Ph 4 | completed | Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus |
Showing 50 of 58 trials
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KENALOG-10 FDA Label Details
Indications & Usage
FDA Label (PDF)KENALOG-10 is indicated for the treatment of Gouty Arthritis; Bursitis; Tenosynovitis; Epicondylitis; Rheumatoid Arthritis; Synovitis of Osteoarthritis; Alopecia Areata; Discoid Lupus Erythematosus; Keloids; Granuloma Annulare; Lichen Planus; Lichen Simplex Chronicus; Psoriatic Plaques; Necrobiosis Lipoidica Diabeticorum.
Track KENALOG-10 with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.